A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Solriamfetol 75 MG
DRUG: Solriamfetol 150 MG
OTHER: Placebo

Sponsor

Massachusetts General Hospital